Chronic Low Back Pain Clinical Trial
— VRGEOfficial title:
Chronic Low Back Pain Graded - Exposure Psychoeducation Intervention
NCT number | NCT03909048 |
Other study ID # | 300002878 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 1, 2019 |
Est. completion date | September 1, 2019 |
Verified date | October 2019 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will examine the effectiveness of one of two psychoeducation treatments on chronic low back pain.
Status | Completed |
Enrollment | 40 |
Est. completion date | September 1, 2019 |
Est. primary completion date | September 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - report having low back pain for more than three months and at least half the days in the past 6 months - be 18-65 years of age, - have scores higher than 37 on the Tampa Scale of Kinesiophobia, Exclusion Criteria: - medical conditions other than back pain that significantly impair movement (e.g., arthritis) - confirmed/suspected pregnancy - pending litigation related to an episode of low back pain - significant impairment in vision |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain Intensity as assessed by Numeric Rating Scale | The Numeric Rating Scale (NRS) measures pain intensity measured via 0-10 numeric rating scale. 0 = No Pain - 10 = Worst Possible Pain Range of scores: 0-10 |
Baseline - Final assessment (average 1 week post treatment) | |
Primary | Present Pain Intensity | Present Pain Intensity (PPI) assesses present pain intensity on a scale of 0 (no pain) to 5 (excruciating) | Baseline - Final assessment (average 1 week post treatment) | |
Primary | Present Pain Rating | Pain Rating Index (PRI) is assessed by 15 questions assessing pain in the sensory and affective dimensions. Items rate from 0 (none) to 3 (severe) on degree to which the words apply to pain. Score Range: 0-45 |
Baseline - Final assessment (average 1 week post treatment) | |
Primary | Pain Chronicity assessed by the Graded Chronic Pain Scale | Pain Chronicity is assessed by the Graded Chronic Pain Scale (GCPS). The GCPS is 7 questions with 3 sub-scales (Characteristic pain intensity, disability score, and disability points). Scoring: Characteristic Pain Intensity: is a 0 to 100 score derived from Questions 1 through 3: Mean (Pain Right Now, Worst Pain, Average Pain) X 10. Disability Score: is 0 to 100 score derived from Questions 4 through 6: Mean (Daily Activities, Social Activities, Work Activities) X 10 Disability Points: Add the indicated points for Disability Days (Question 7) and for Disability Score (0-6). Items rate from 0 to 10 with 0 referencing no pain/interference/change and 10 referencing pain as bad as could be/unable to carry out any activities/extreme change. |
Baseline - Final assessment (average 1 week post treatment) | |
Primary | Daily Pain Monitoring: 10 point scale | Daily pain monitoring defined as daily pain intensity and daily pain interference monitoring is two questions asked daily on a 10 point scale assessing daily pain and how much pain had interfered with day to day activities. Pain: Over the past 24 hours, how would you rate your back pain on average? (0=No Pain; 10=Worst Imaginable Pain) Interference: Over the past 24 hours, how much did pain interfere with your day-to-day activities? (0=No Interference; 10 = A great deal of interference)" |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Back Disability as assessed by the Roland Morris Disability Questionnaire | The Roland Morris Disability Questionnaire (RMDQ) assesses disability due to low back pain. The RMDQ is a 24 item survey with yes/no response options. Score 0 -24 with ower scores indicate more impairment. |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Depressive symptoms as assessed by the Center for Epidemiologic Studies Depression Scale | The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20 item survey tool. The items are a 4 pt Likert response items. Scores range from 0-60 with higher scores indicate greater levels of depressive symptoms. |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Pain Catastrophizing as assessed by the Pain Catastrophizing Scale | The Pain Catastrophizing Scale (PCS) is a 13 item survey assessing catastrophizing in context to pain. There are 13 items with 5-pt Likert responses. There are several subscales. Scoring Procedure: The PCS total score is computed by summing responses to all 13 items (0-52). Subscales: Rumination: Sum of items 8, 9, 10, 11 (0-16). Magnification: Sum of items 6, 7, 13 (0-12). Helplessness: Sum of items 1, 2, 3, 4, 5, 12 (0-24). |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Pain-related fear of movement as assessed by the Tampa Scale Kinesiophobia | The Tampa Scale Kinesiophobia (TSK) is a 17 item assessment of fear of movement. This uses a 5-pt Likert scale from 1 = Strongly Disagree to 4 = Strongly Agree. Scoring Procedure: Sum items Range: 17-68 Subscale Harm/Somatic Items: 3, 5, 6, 9, 11, 15 Subscale Avoidance Items: 1, 2, 7, 10, 13, 14, 17 |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Mood and Affect as assessed by the Positive and Negative Affect Scale | The Positive and Negative Affect Scale (PANAS) measures mood of participants. This is a 20 item survey with 5 pt Likert response indicating to what degree the participant feels those emotions. There is a positive and negative subscale. Higher positive affect score indicates greater positive emotions; higher negative affect score indicates greater negative emotions. Range of Scores: 0-40 |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Immersive Tendencies | Immersive Tendencies are assessed by the Immersive Tendencies Questionnaire (ITQ). This is an 18-item survey. Item responses use a 7 point Likert scale. Subscales include: focus, involvement, emotions, and play. Each subscale is scored by summing items. A total score is scored by summing all items. Range of total score: 18-126 Focus range of scores: 5-35 Involvement range of scores: 5-35 Emotions range of scores: 4-28 Play range of scores: 3-21 Higher scores indicate higher immersive tendencies overall and in each sub-scale. |
Baseline only | |
Secondary | Absorption Tendencies | Tellegen Absorption Scale is a 34-item multi-dimensional measure that assesses imaginative involvement and the tendency to become mentally absorbed in everyday activities. Item responses are on a 5-point Likert scale. Items are summed to score. Range of scores: 0-136. Higher scores indicate greater levels of absorption. |
Baseline Only | |
Secondary | Video Game History | History of playing video games. | Baseline Only | |
Secondary | Patient Treatment Evaluation as assessed by the Modified Treatment Evaluation Inventory | Patient treatment evaluation is assessed by Treatment Evaluation Inventory. This is a 9 item scale with a 5-point Likert responses for each question. The items are scored by summing all items. Range of scores: 9-45. A higher score indicates greater acceptance of treatment. |
Final assessment (average 1 week post treatment) | |
Secondary | Patient Treatment Evaluation as assessed by Semi-structured Qualitative interviewing | Patient treatment evaluation is assessed by semi-structured interviewing. Qualitative feedback from participant experience will be assessed by thematic analyses. | Final assessment (average 1 week post treatment) | |
Secondary | Daily intervention feedback questions | The daily intervention feedback questions are 7 items that assess the individuals feelings and experiences during that daily intervention session. 0-10 Likert scale Each item is it's own scale. Higher scores indicate more enjoyment/usefulness/demand/awareness/concern/mood. |
Baseline - Final assessment (average 1 week post treatment) | |
Secondary | Patient Treatment Evaluation as assessed by the Usefulness, Satisfaction, and Ease of Use Questionnaire | The Usefulness, Satisfaction, and Ease of Use Questionnaire (USE, Lund, 2001) measures the subjective usability of a product or service. It is a 30-item survey that examines four dimensions of usability: usefulness, ease of use, ease of learning, and satisfaction. This metric can be applied to various scenarios of usability assessment because it is non-proprietary and technology-agnostic. is a 30 item survey. Each item is presented on a 7-point Likert scale from strongly disagree = 1 to strongly agree. = 7 Each subscale is calculated by averaging all items in subscale. Usefulness: items 1-8 Ease of use: items 9-19 Ease of Learning: items 20-23 Satisfaction: items 24-30 Range of scores for each subscale: 1-7 Scoring Interpretation: Higher score indicates greater usefulness, satisfaction, and ease of use. |
Final assessment (average 1 week post treatment) | |
Secondary | Patient Treatment Evaluation as assessed by the Patient Global Impression of Change Scale | Patient treatment evaluation is assessed by the Patient Global Impression of Change. This is a one item 7 point Likert item assessing improvement of the participants overall status. Item responses: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse |
Final assessment (average 1 week post treatment) | |
Secondary | Video Game Preferences as assessed by the BrainHex | Video game preferences will be assessed by the BrainHex. The BrainHex provides a tool for designing gameplay and understanding motivations for play. | Final assessment (average 1 week post treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 |